Multiple systemic expression of human inferferon-β in mice can be achieved upon repeated administration of optimized pcTG90-lipoplex

被引:21
作者
Meyer, O [1 ]
Schughart, K [1 ]
Pavirani, A [1 ]
Kolbe, HVJ [1 ]
机构
[1] Transgene SA, Vectorol & Biochem, F-67082 Strasbourg, France
关键词
in vivo gene transfer; systemic expression; repeated administration; human interferon-beta; lipoplex formulation;
D O I
10.1038/sj.gt.3301289
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The possibility of achieving multiple systemic expression of human interferon-beta in mice upon repeated intravenous administration of cationic liposome-DNA complex (lipoplex) was investigated. Lipoplexes containing the pentammonio lipid pcTG90 were first optimized by selecting the most efficient ratio of pcTG90 to phosphatidylethanolamine (DOPE) and the N/P ratio of cationic lipid nitrogen to DNA phosphate. Highest levels and reproducibility of gene expression were obtained using pcTG90/DOPE (1:2) liposomes complexed with the IFNB1 gene containing plasmid pTG14169 at a N/P ratio of 10. Following lipoplex administration, an early but transient human interferon-beta expression in serum was observed importantly, repeated systemic gene expression could be achieved upon re-administration with a minimal time interval of 14 days between two injections. For an interval period of 6 days, subsequent gene expression was inhibited by a first administration of lipoplexes containing either a luciferase reporter gene plasmid or an empty plasmid, but was not inhibited when free (noncomplexed) plasmid pTG14169 was first injected. Multiple injections of pcTG90-lipoplex performed once every other month resulted in three subsequent peaks of systemic IFNB1 gene expression in mice. In conclusion, our study demonstrates the feasibility of expanding the therapeutic window of a cytokine using repetitive intravenous administration of lipoplex.
引用
收藏
页码:1606 / 1611
页数:6
相关论文
共 25 条
[1]  
BARTLETT GR, 1959, J BIOL CHEM, V234, P466
[2]   Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene [J].
Blezinger, P ;
Wang, JJ ;
Gondo, M ;
Quezada, A ;
Mehrens, D ;
French, M ;
Singhal, A ;
Sullivan, S ;
Rolland, A ;
Ralston, R ;
Min, W .
NATURE BIOTECHNOLOGY, 1999, 17 (04) :343-348
[3]   TRANSFER OF GENES TO HUMANS - EARLY LESSONS AND OBSTACLES TO SUCCESS [J].
CRYSTAL, RG .
SCIENCE, 1995, 270 (5235) :404-410
[4]   Why do so many cancer patients fail to respond to interferon therapy? [J].
Einhorn, S ;
Grander, D .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (04) :275-281
[5]   Nomenclature for synthetic gene delivery systems [J].
Felgner, PL ;
Barenholz, Y ;
Behr, JP ;
Cheng, SH ;
Cullis, P ;
Huang, L ;
Jessee, JA ;
Seymour, L ;
Szoka, F ;
Thierry, AR ;
Wagner, E ;
Wu, G .
HUMAN GENE THERAPY, 1997, 8 (05) :511-512
[6]  
Gao X, 1995, GENE THER, V2, P710
[7]   Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery [J].
Hong, KL ;
Zheng, WW ;
Baker, A ;
Papahadjopoulos, D .
FEBS LETTERS, 1997, 400 (02) :233-237
[8]  
Kreiss P, 1999, J GENE MED, V1, P245, DOI 10.1002/(SICI)1521-2254(199907/08)1:4<245::AID-JGM49>3.0.CO
[9]  
2-G
[10]   NONVIRAL GENE-THERAPY - THE PROMISE OF GENES AS PHARMACEUTICAL PRODUCTS [J].
LEDLEY, FD .
HUMAN GENE THERAPY, 1995, 6 (09) :1129-1144